Paper Details

  1. Home
  2. Paper Details

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.

Author: CastagnaAntonella, EsserStefan, HaubrichRichard, LlibreJosep M, MargotNicolas, McNichollIan R, MolinaJean-Michel, Perez-ValeroIgnacio, PiontkowskyDavid, PulidoFederico, ShaoYongwu, TemmeLauren

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in individuals with specific resistance mutations when switching from other HIV treatment regimens. The study aimed to assess the effectiveness of E/C/F/TAF in individuals with resistance mutations.
Paper Details　
Original Abstract of the Article :
The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate-based or abacavir (ABC)-based re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899215/

データ提供：米国国立医学図書館（NLM）

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Promising Treatment Option for HIV-Positive Individuals with M184V/I Mutation

The management of HIV infection requires continuous research and development of effective and safe treatment regimens. This study explores the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in individuals with HIV and the M184V/I mutation, a genetic variant associated with resistance to certain antiretroviral drugs. This study aimed to assess the effectiveness of switching to E/C/F/TAF in individuals with HIV who have developed resistance to other antiretroviral medications. This research used a retrospective observational study to evaluate the virological suppression outcomes after switching to E/C/F/TAF.

E/C/F/TAF: A Potential Solution for HIV Treatment Challenges

The study found that switching to E/C/F/TAF resulted in sustained virologic suppression in a significant proportion of participants with the M184V/I mutation. This finding suggests that E/C/F/TAF could be a viable option for individuals with HIV who have developed resistance to other antiretroviral drugs. This research underscores the importance of exploring new treatment strategies to address emerging challenges in HIV management. The study also highlights the potential benefits of E/C/F/TAF in overcoming resistance and achieving sustained viral suppression.

A New Path Forward in HIV Treatment

The study's findings provide valuable insights into the potential of E/C/F/TAF as a treatment option for individuals with HIV and the M184V/I mutation. This research could lead to improved treatment outcomes for this vulnerable population and contribute to a more effective and comprehensive approach to managing HIV infection. This development could potentially enhance the quality of life for individuals living with HIV, offering them a brighter and healthier future.

Dr.Camel's Conclusion

Just as a camel navigates the vast and unforgiving desert, the journey to effectively manage HIV infection is fraught with challenges. This study sheds light on a potential oasis in the form of E/C/F/TAF, a promising treatment option for individuals with the M184V/I mutation. This research holds the potential to reshape the landscape of HIV treatment, offering a more effective and sustainable path towards a healthier future.

Date :
  1. Date Completed 2021-09-10
  2. Date Revised 2023-09-26
Further Info :

Pubmed ID

33315694

DOI: Digital Object Identifier

PMC7899215

Related Literature

Article Analysis
・Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.